FDA probes cognitive impact of new cholesterol drugs; Regeneron, Sanofi …Reuters(Reuters) – The U.S. Food and Drug Administration has called for an assessment of potential neurocognitive side effects of an experimental cholesterol drug being developed by Regeneron and Sanofi, Sanofi said in its annual report on Friday. The regulatory …Sanofi, Regeneron Must Assess Brain Risk in New Cholesterol DrugBusinessweekRegeneron, Sanofi and Amgen shares suffer on FDA’s frets about PCSK9 classFierceBiotechFDA asks Sanofi, Regeneron to assess cholesterol drug’s cognitive risksChicago Tribune (blog)StreetInsider.com (subscription) -Investor’s Business Dailyall 8 news articles …read more
Via: Google USA
FDA probes cognitive impact of new cholesterol drugs; Regeneron, Sanofi ... - Reuters
Real Estate of Cebu
